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Letter to the Editor 
 
A recent editorial in Nature titled ‘Animal Farm’ argued against a lobbying campaign that aims to prevent 
animals from being used for addiction research1, rebutting the view from the lobbyists that ‘addiction is a 
social problem’ and claiming instead that it is a ‘brain disease’. It seems to us that the authors of the editorial 
mirrored the mistake being made by the lobbyists in ignoring a large body of research that does not fit their 
world view: evidence showing that addiction is socially patterned, and that prevalence responds to 
influences that do not need to assume pathology, such as social marketing campaigns (in the case of 
smoking), price rises (tobacco and alcohol), recovery without treatment arising from a change in personal 
circumstances, and restrictions on availability2.  
 
Readers of Addiction will be familiar with the perennial debate about the extent to which addiction is a brain 
disease.3-12 After many decades of research in this area, it must be preferable to frame the problem in terms 
that permit the gamut of potentially effective interventions to be harnessed, not just those that focus on 
pathological failures in choice or executive control mechanisms or powerful acquired drives13.  
 
George Orwell coined the term ‘doublethink’ to refer to the act of holding contradictory views in different 
contexts. When it comes to a socially defined construct such as addiction, where definitions serve a 
utilitarian function, this is no bad thing. In fact, there are well-articulated models that can explain addiction 
in terms that permit a focus on biological, psychological and social aspects depending on the context. These 
models (e.g. PRIME Theory2) bring together such apparently diverse zeitgeists into coherent explanations 
that make predictions for effectiveness of interventions that are borne out by the evidence2,13. It would be 
helpful if people working in the field across the spectrum from basic to social science would set their 
research agenda within these integrative approaches so that we can make faster progress and apply the 
knowledge gained more effectively. 
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